Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss due to the targeting of anagen hair follicles by the host immune system. The primary…
Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) and characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from the chronic…
Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…
CAR T-cell therapies have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) and more recently to patients with R/R multiple myeloma. Priced at more than $350,…
Amyotrophic lateral sclerosis (ALS) is a progressively debilitating disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of…
The multiple sclerosis (MS) therapy market continues to evolve, with each new FDA-approved disease-modifying therapy (DMT) further expanding treatment choices. The newest entrants (e.g., Zeposia,…
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. It is caused by a mutation in one hemoglobin beta (HBB) gene (beta thalassemia minor) or a…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have…
Scleroderma, also known as systemic sclerosis (SSc), is characterized by progressive vasculopathy, progressive fibrosis, and autoimmunity. While disease severity and symptoms are heterogeneous, in…
Tumor necrosis factor (TNF)-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira, biosimilars of both drugs where available) are the mainstay of biological treatment for moderate to…
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or…
An increasing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form…